Clinical Outcomes of Patients with HER2 Positive Metastatic Breast Cancer to the Brain, with First-Line Trastuzumab, Pertuzumab and Chemotherapy, in a Real-World Setting
Sarah Sharman Moser,1 Lior Apter,1,2 Idit Livnat,3 Roni Ginsburg,3 Adva Yarden,3 Michal Drori,1 Anat Drizon,1 Gabriel Chodick,1,4 Nava Siegelmann-Danieli1,4 1Maccabi Institute for Research and Innovation (Maccabitech), Maccabi Healthcare Services, Tel Aviv, Israel; 2Department of Health Systems Mana...
Main Authors: | Sharman Moser S, Apter L, Livnat I, Ginsburg R, Yarden A, Drori M, Drizon A, Chodick G, Siegelmann-Danieli N |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2024-03-01
|
Series: | Breast Cancer: Targets and Therapy |
Subjects: | |
Online Access: | https://www.dovepress.com/clinical-outcomes-of-patients-with-her2-positive-metastatic-breast-can-peer-reviewed-fulltext-article-BCTT |
Similar Items
-
Patient with metastatic breast cancer, HER2-positive, trastuzumab- and pertuzumab-resistant responding to lapatinib
by: Daniela Cianniello, et al.
Published: (2018-06-01) -
Targeting HER2/HER3 co‐mutations in metastatic breast cancer: Case reports of exceptional responders to trastuzumab and pertuzumab therapy
by: Page E. Blas, et al.
Published: (2024-03-01) -
T-DM1 after Pertuzumab plus Trastuzumab: Treatment Sequence-Induced Selection Bias in HER2-Positive Metastatic Breast Cancer
by: Thibaut Sanglier, et al.
Published: (2022-05-01) -
Comparing pyrotinib with trastuzumab and pertuzumab with trastuzumab for HER2-positive metastatic breast cancer: a retrospective, multicenter analysis
by: Shuhui You, et al.
Published: (2023-12-01) -
First line chemotherapy plus trastuzumab in metastatic breast cancer HER2 positive - Observational institutional study
by: Meryem Aitelhaj, et al.
Published: (2016-08-01)